In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand

[1]  G. Denardo,et al.  Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. , 1997, Anticancer research.

[2]  I. Pastan,et al.  Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  C. Sturiale,et al.  Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors , 1994, Cancer.

[4]  A. Maraveyas,et al.  Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer , 1994 .

[5]  T. Koike,et al.  Novel bifunctional macrocyclic chelating agents appended with a pendant-type carboxymethylamino ligand and nitrobenzyl group and stability of the 88YIII complexes , 1993 .

[6]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[7]  R. Delgado,et al.  The stability of the metal complexes of cyclic tetra-aza tetra-acetic acids. , 1992, Talanta.

[8]  M. Brechbiel,et al.  Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.

[9]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[10]  S. Larson Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. , 1991, Journal of the National Cancer Institute.

[11]  J. Schlom,et al.  Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. , 1991, Cancer research.

[12]  R. Reilly Radioimmunotherapy of malignancies. , 1991, Clinical pharmacy.

[13]  K. D. Hardman,et al.  In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.

[14]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[15]  J. Schlom,et al.  Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. , 1990, Journal of the National Cancer Institute.

[16]  J. Schlom,et al.  Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. , 1989, Surgery, gynecology & obstetrics.

[17]  S. Mirzadeh,et al.  Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[19]  J. Schlom,et al.  Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. , 1988, Cancer research.

[20]  D. E. Simpson,et al.  Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  M. Brechbiel,et al.  212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. , 1988, Journal of the National Cancer Institute.

[22]  D. Hnatowich,et al.  Generator-produced yttrium-90 for radioimmunotherapy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Salvatore,et al.  Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum , 1987, Diseases of the colon and rectum.

[24]  D. E. Simpson,et al.  New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  S. Larson,et al.  Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. , 1987, Cancer research.

[26]  J L Humm,et al.  Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  S. Larson,et al.  Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. , 1984, Cancer research.

[28]  P. Hand,et al.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[30]  G. Denardo,et al.  Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. , 1994, Advances in experimental medicine and biology.

[31]  A. Maraveyas,et al.  Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. , 1994, Cancer.

[32]  P. Hand,et al.  Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). , 1993, Biotechnology therapeutics.

[33]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[34]  M. Kuroki,et al.  TAG-72 as a Tumor Marker , 1992 .

[35]  S. Mirzadeh,et al.  Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[36]  O. Gansow Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[37]  M. Brechbiel,et al.  An effective chelating agent for labelling of monoclonal antibody with 212Bi for α-particle mediated radioimmunotherapy , 1991 .

[38]  J. Wesolowski,et al.  Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. , 1990, Human antibodies and hybridomas.

[39]  S. Mirzadeh,et al.  Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.

[40]  A. M. Friedman,et al.  An improved generator for the production of 212Pb and 212Bi from 224Ra. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.